Drug Search Results
More Filters [+]

Vobarilizumab

Alternative Names: vobarilizumab, alx-0061
Latest Update: 2019-11-04
Latest Update Note: News Article

Product Description

Mechanisms of Action: IL6 Inhibitor

Novel Mechanism: No

Modality: Antibody

Route of Administration: Intravenous,Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Vobarilizumab

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Arthritis, Rheumatoid|Lupus Erythematosus, Systemic

Phase 1: Arthritis, Rheumatoid

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2014-003034-42

P2

Completed

Arthritis, Rheumatoid

2018-08-14

ALX0061-C203

P2

Completed

Arthritis, Rheumatoid

2018-08-01

STEADY

P2

Completed

Lupus Erythematosus, Systemic

2018-01-16

ALX0061-C204

P2

Completed

Lupus Erythematosus, Systemic

2018-01-01

Recent News Events